These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37266188)

  • 1. Clinical Implications of Kratom (
    Prevete E; Kuypers KPC; Theunissen EL; Esposito G; Ramaekers JG; Pasquini M; Corazza O
    Curr Addict Rep; 2023; 10(2):317-334. PubMed ID: 37266188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the self-reported motivations of kratom (
    Grundmann O; Veltri CA; Morcos D; Knightes D; Smith KE; Singh D; Corazza O; Cinosi E; Martinotti G; Walsh Z; Swogger MT
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):433-444. PubMed ID: 35389321
    [No Abstract]   [Full Text] [Related]  

  • 3. Kratom use and mental health: A systematic review.
    Swogger MT; Walsh Z
    Drug Alcohol Depend; 2018 Feb; 183():134-140. PubMed ID: 29248691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kratom policy: The challenge of balancing therapeutic potential with public safety.
    Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
    Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic.
    Garcia-Romeu A; Cox DJ; Smith KE; Dunn KE; Griffiths RR
    Drug Alcohol Depend; 2020 Mar; 208():107849. PubMed ID: 32029298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kratom's Emergence and Persistence Within the US Polydrug Epidemic.
    Smith KE; Rogers JM; Feldman JD
    Curr Addict Rep; 2023; 10(2):262-271. PubMed ID: 37266191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users.
    Singh D; Müller CP; Vicknasingam BK
    Drug Alcohol Depend; 2014 Jun; 139():132-7. PubMed ID: 24698080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa).
    Hartley C; Bulloch M; Penzak SR
    J Clin Pharmacol; 2022 May; 62(5):577-593. PubMed ID: 34775626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Adverse Cardiovascular Effects and Cardiotoxicity of Kratom (
    Leong Bin Abdullah MFI; Singh D
    Front Pharmacol; 2021; 12():726003. PubMed ID: 34646135
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia.
    Singh D; Müller CP; Murugaiyah V; Hamid SBS; Vicknasingam BK; Avery B; Chear NJY; Mansor SM
    J Ethnopharmacol; 2018 Mar; 214():197-206. PubMed ID: 29248450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.
    Lydecker AG; Sharma A; McCurdy CR; Avery BA; Babu KM; Boyer EW
    J Med Toxicol; 2016 Dec; 12(4):341-349. PubMed ID: 27752985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature.
    Stanciu C; Ahmed S; Gnanasegaram S; Gibson S; Penders T; Grundmann O; McCurdy C
    Am J Drug Alcohol Abuse; 2022 Sep; 48(5):509-528. PubMed ID: 36001875
    [No Abstract]   [Full Text] [Related]  

  • 13. A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.
    Prevete E; Kuypers KPC; Theunissen EL; Corazza O; Bersani G; Ramaekers JG
    Hum Psychopharmacol; 2022 Jan; 37(1):e2805. PubMed ID: 34309900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations of kratom (Mitragyna speciosa Korth.) tea bag preparations and reported pharmacological effects.
    Grundmann O; Hill K; Al Barzanji E; Hazrat NG; Kaur G; Negeve RE; Shade S; Weber S; Veltri CA
    J Ethnopharmacol; 2023 Dec; 317():116779. PubMed ID: 37364801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study.
    Schimmel J; Amioka E; Rockhill K; Haynes CM; Black JC; Dart RC; Iwanicki JL
    Addiction; 2021 Jan; 116(1):176-181. PubMed ID: 32285981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Future Potential Impact of COVID-19 on Kratom (
    Singh D; Brown PN; Cinosi E; Corazza O; Henningfield JE; Garcia-Romeu A; McCurdy CR; McMahon LR; Prozialeck WC; Smith KE; Swogger MT; Veltri C; Walsh Z; Grundmann O
    Front Psychiatry; 2020; 11():574483. PubMed ID: 33324252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kratom (Mitragyna speciosa): Friend or Foe?
    Sethi R; Hoang N; Ravishankar DA; McCracken M; Manzardo AM
    Prim Care Companion CNS Disord; 2020 Jan; 22(1):. PubMed ID: 31999896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users.
    Smith KE; Bunting AM; Walker R; Hall MT; Grundmann O; Castillo O
    J Psychoactive Drugs; 2019; 51(4):311-322. PubMed ID: 30961450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia.
    Singh D; Narayanan S; Vicknasingam B; Corazza O; Santacroce R; Roman-Urrestarazu A
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28544011
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.